Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.
about
Interferon for Hepatitis C Virus in Hemodialysis--an Individual Patient Meta-analysis of Factors Associated with Sustained Virological ResponseManaging chronic hepatitis C in the difficult-to-treat patientDiagnosis, management, and treatment of hepatitis C: an updatePilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection.Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center studyNanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Hepatitis C virus infection and dialysis: 2012 update.Management of the kidney transplant patient with chronic hepatitis C infectionManagement of chronic hepatitis C: consensus guidelines.HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirinEfficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.Treatment of chronic hepatitis C in hemodialysis patients.Treatment of hepatitis C virus infection in patients with end-stage renal disease.Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C.Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy.Pegylated interferon for treatment in hemodialysis patients with chronic hepatitis C.
P2860
Q27489433-331E1B64-29C4-4EAA-AD4C-72D2B6ACF819Q27490409-673CA946-FB2D-459F-A463-A4CB25909383Q29619682-0D16B68F-BEEF-481E-ADAC-56535485CD49Q33374217-6DA04F21-EA39-4695-AFB1-F14AE95B9D14Q33434493-1292B7C8-5F6B-4C1A-B1AC-B06DC34BBCF9Q33559298-619D4E84-4F69-439B-BE07-7A8F6979CF28Q33710828-9F956955-C617-40CA-816B-2A58DE4F6E10Q34988932-D6352253-9956-4918-BCE0-80E6CD95E314Q36849347-22EADD1B-1B74-4DEB-8E02-5301D939FEBEQ37025954-C349BDC4-43C6-4E51-BD90-710F40D3620CQ37174162-34AD50A1-0963-402C-A621-C9B6111B2E39Q37313163-3839696C-0603-419B-8335-FFEEAF864ADEQ37831965-A509A1D7-63B8-4CF3-A95C-E387F1941AEEQ42982413-12967C3E-CE28-40BF-8C39-C47ECE71C7C1Q42997177-C0A168E4-040C-41B9-8A65-82151E8DEFA3Q50556069-4C522EAA-35A6-4655-953E-63DC3C4B211DQ50576430-97B89BF1-B966-4336-B368-FE7BB7D8E925
P2860
Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Efficacy and tolerability of p ...... ents with chronic hepatitis C.
@ast
Efficacy and tolerability of p ...... ents with chronic hepatitis C.
@en
type
label
Efficacy and tolerability of p ...... ents with chronic hepatitis C.
@ast
Efficacy and tolerability of p ...... ents with chronic hepatitis C.
@en
prefLabel
Efficacy and tolerability of p ...... ents with chronic hepatitis C.
@ast
Efficacy and tolerability of p ...... ents with chronic hepatitis C.
@en
P2093
P2860
P1476
Efficacy and tolerability of p ...... ents with chronic hepatitis C.
@en
P2093
Ali Cetinkaya
Bulent Kantarceken
Hasan Uçmak
Ismet Onder Isik
Mehmet Akif Buyukbese
Omer Faruk Kokoglu
Salih Hosoglu
P2860
P304
P356
10.1111/J.1440-1746.2005.04008.X
P577
2006-03-01T00:00:00Z